(Q44232151)

English

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.

scientific article published on 30 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Robert I Griffiths

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Michelle L Gleeson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Joseph Mikhael

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Martin H Dreyling

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

0 references

publication date

30 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

6079-6088

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648454%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Development of a comorbidity index using physician claims data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Cost of care for elderly cancer patients in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Estimating causal effects from large data sets using propensity scores

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Linear regression analysis of censored medical costs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Limits of observational data in determining outcomes from cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

21 January 2018

Limits on Medicare's ability to control rising spending on cancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27638

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44232151&oldid=2108796358"